RecruitingPhase 3NCT07549412

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Studying Esophageal atresia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
EMD Serono Research & Development Institute, Inc.
Principal Investigator
Medical Responsible
EMD Serono Research & Development Institute, Inc.
Intervention
Precemtabart tocentecan(drug)
Enrollment
1020 enrolled
Eligibility
18 years · All sexes
Timeline
20262029

Study locations (3)

Collaborators

Merck KGaA, Darmstadt, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07549412 on ClinicalTrials.gov

Other trials for Esophageal atresia

Additional recruiting or active studies for the same condition.

See all trials for Esophageal atresia

← Back to all trials